Drug resistance emergence in macaques administered cabotegravir long-acting for pre-exposure prophylaxis during acute SHIV infection
Long-acting formulation of the integrase inhibitor cabotegravir (CAB LA) is in clinical development for HIV pre-exposure prophylaxis (PrEP). Here, using a SHIV macaque model, the authors show emergence of integrase mutations associated to CAB LA PrEP that confer pan-integrase inhibitor resistance.
Guardado en:
Autores principales: | Jessica Radzio-Basu, Olivia Council, Mian-er Cong, Susan Ruone, Alicia Newton, Xierong Wei, James Mitchell, Shanon Ellis, Christos J. Petropoulos, Wei Huang, William Spreen, Walid Heneine, J. Gerardo García-Lerma |
---|---|
Formato: | article |
Lenguaje: | EN |
Publicado: |
Nature Portfolio
2019
|
Materias: | |
Acceso en línea: | https://doaj.org/article/d248393d33e74833a7f91fb2b8224578 |
Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
Ejemplares similares
-
CTL-mediated immunotherapy can suppress SHIV rebound in ART-free macaques
por: Jin Fan, et al.
Publicado: (2019) -
Antibody-based CCR5 blockade protects Macaques from mucosal SHIV transmission
por: Xiao L. Chang, et al.
Publicado: (2021) -
Persistence of viral RNA in lymph nodes in ART-suppressed SIV/SHIV-infected Rhesus Macaques
por: Anthony M. Cadena, et al.
Publicado: (2021) -
Effective Prophylaxis of COVID-19 in Rhesus Macaques Using a Combination of Two Parenterally-Administered SARS-CoV-2 Neutralizing Antibodies
por: Brandon J. Beddingfield, et al.
Publicado: (2021) -
Analysis of multiply spliced transcripts in lymphoid tissue reservoirs of rhesus macaques infected with RT-SHIV during HAART.
por: Jesse D Deere, et al.
Publicado: (2014)